SCHEMBL12907182

SCHEMBL12907182

Nc1n[nH]c2ccc(-c3ccc(C(F)(F)F)cc3)cc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 14/20 0.69
CDC7 O00311 2/20 0.54
MAP2K4 P45985 2/20 0.52
MAPK1 P28482 1/20 0.52
MAPKAPK2 P49137 1/20 0.52
MAPKAPK3 Q16644 1/20 0.52
MAPK6 Q16659 1/20 0.52
JAK3 P52333 4/20 0.52
TYK2 P29597 3/20 0.52
PLK4 O00444 2/20 0.52
DAPK3 O43293 2/20 0.52
DYRK3 O43781 2/20 0.52
ROCK2 O75116 2/20 0.52
MAP4K4 O95819 2/20 0.52
CDK1 P06493 2/20 0.52
CDK2 P24941 2/20 0.52
MARK3 P27448 2/20 0.52
CLK2 P49760 2/20 0.52
CDK5 Q00535 2/20 0.52
PRKCD Q05655 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907202 0.87 PDPK1 (0.69) JAK2JAK3PLK4ROCK2CDK2
SCHEMBL2409215 0.86 MAP2K4 (0.58) JAK2CDC7MAP2K4MAPK1MAPKAPK2
SCHEMBL12907220 0.86 JAK2 (0.65) JAK2MAP2K4MAPK1MAPKAPK2MAPKAPK3
SCHEMBL1142228 0.86 JAK2 (0.64) JAK2CDC7MAPK1JAK3TYK2
Hydrochloric Acid SCHEMBL1141989 0.84 JAK2 (0.62) JAK2CDC7MAPK1JAK3TYK2
SCHEMBL10213929 0.84 JAK2 (0.81) JAK2CDC7JAK3TYK2PLK4
SCHEMBL12907189 0.84 JAK2 (0.66) JAK2CDC7JAK3TYK2PLK4
SCHEMBL31690865 0.81 JAK2 (1.00) JAK2CDC7JAK3TYK2PLK4
SCHEMBL12907171 0.81 JAK2 (0.72) JAK2CDC7MAPK1JAK3TYK2
SCHEMBL12907183 0.80 JAK2 (0.60) JAK2CDC7JAK3TYK2PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
EP-1765788-B1 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GMBH (DE) 2009-06-03 EP disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232620-A1 3-Aminoindazoles SGK3, SGK1, SGK2 JAK2 562/4885CDC7 755/4885MAP2K4 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.